Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Developmental therapeutics

2093 - Dose Escalation/Expansion Study to Investigate the Safety, Pharmacokinetics, Food Effect, and Antitumor Activity of BGB-290 in Patients with Advanced Solid Tumors


09 Sep 2017


Developmental therapeutics


Jason Lickliter


Annals of Oncology (2017) 28 (suppl_5): v122-v141. 10.1093/annonc/mdx367


J. Lickliter1, L. Mileshkin2, M. Voskoboynik3, M. Millward4, A. Freimund2, T. Meniawy5, T. Tang6, R. Wei6, M. Li7, V. Paton8

Author affiliations

  • 1 Oncology, Nucleus Network, 3004 - Melbourne/AU
  • 2 Oncology, Peter MacCallum Cancer Center, 3002 - Melbourne/AU
  • 3 Oncology, Nucleus Network, Melbourne/AU
  • 4 Oncology, Clinical Linear Research, 6009 - Nedlands/AU
  • 5 Oncology, Linear Clinical Research Limited, 6009 - Nedlands/AU
  • 6 Clinical Pharmacology, BeiGene USA, Inc., Emeryville/US
  • 7 Clinical Development, BeiGene Co. Ltd, Beijing/CN
  • 8 Oncology, BeiGene, Inc, Emeryville/US


Abstract 2093


Poly (ADP-ribose) polymerase inhibitors (PARPis) represent a class of antitumor agents that exert their cytotoxic effects by inhibiting PARP activity. Some PARPis are capable of trapping PARP proteins on DNA further augmenting cell death. BGB-290 is a potent and selective PARP1/2 inhibitor with strong PARP-trapping and antitumor activity in both in vitro and in vivo preclinical tumor models harboring BRCA gene mutations or other homologous recombination defects.


This two-staged study (NCT02361723) consists of a Phase 1A dose-escalation/dose-finding component to establish the maximum tolerated dose (MTD) and/or recommended Phase 2 dose (RP2D) of BGB-290 in patients with solid tumors and a two-part Phase 2 component that includes expansion in targeted indications (Part A) and the effect of food on the BGB-290 pharmacokinetic (PK) profile (Part B).


As of 1 May 2017, Phase 1A had completed enrollment (n = 45); 3 patients remain on treatment. Objective responses were observed across the dose range (2.5–120 mg BID). Of the 23 evaluable patients with gynecological cancer, 10 (43%) achieved an objective response per RECIST 1.1 (n = 3 complete; n = 7 partial). More patients with germline BRCA 1/2 mutated ovarian cancer achieved an objective response (n = 7/12, 58%) than patients not carrying the mutation (n = 2/8, 25%). Drug-related adverse events (AEs) reported in ≥ 10% of patients were nausea, fatigue, anemia, vomiting, diarrhea, anorexia and neutropenia. Anemia and neutropenia were the most common drug-related Grade 3 AEs; no Grade 4 drug-related AEs were reported. Three BGB-290-related serious AEs were reported (anemia, n = 2; nausea, n = 1). Four deaths were associated with an AE; however, none were considered drug-related. The BGB-290 RP2D was determined as 60 mg BID and is being evaluated in Phase 2 to determine antitumor activity and food effects. Dose escalation to determine MTD with QD dosing is ongoing.


BGB-290 has demonstrated a favorable safety profile and promising preliminary antitumor activity in phase 1A; phase 2 is ongoing evaluating in patients with ovarian, breast, prostate, gastric and small cell lung cancer.

Clinical trial identification

NCT02361723, January 29, 2015

Legal entity responsible for the study

Beigene Ltd.


Beigene Ltd.


T. Meniawy: Non-financial support and other from Beigene during the conduct of the study. T. Tang, R. Wei, M. Li, V. Paton: Employee of BeiGene. All other authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.